Authors
Latest:
ASCO: New data for Alecensa shows 5-year overall survival in ALK-positive NSCLCOn Friday 29 May at the ASCO20 Virtual Scientific Programme, Roche presented updated data from the pivotal phase III ALEX clinical study.
Latest:
ESMO Data Show More Can Be Done for Cancer of Unknown Primary PatientsTwo research papers presented by Roche and Foundation Medicine at the 2019 European Society of Medical Oncology (ESMO) Annual Meeting demonstrate both the promise of an innovative precision medicine driven clinical trial for patients with cancer of unknown primary, as well as the challenges of identifying eligible patients for the trial, according to ESMO guidelines.
Latest:
Biosimilars in Cancer Care: Potentially Improving Patient Access to Essential Therapies9,10Gary Fanjiang, MD, vice president of Biosimilars Global Development, Amgen, discusses the development of biosimilars and some of the clinical considerations related to their use.
Latest:
TIL Therapy May Provide Second-Line Option for Cervical CancerInvestigators are optimistic that LN-145, an autologous tumor-infiltrating lymphocyte investigational therapy, could be a potential treatment option for patients with recurrent, metastatic, or persistent cervical cancer.
Latest:
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Offers Subcutaneous CD38-Directed Antibody to Health Care Providers and Their Multiple Myeloma PatientsSince the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.
Latest:
Targeted Treatment Helps Delay ALK+ mNSCLC ProgressionRemarkable progress has been made in the treatment of ALK+ mNSCLC patients, and the field continues to grow at a rapid pace.
Latest:
Dr. Aithal on the HERceptin Adjuvant (HERA) TrialSramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.
Latest:
Dr. Verstovsek on the Potential Role of Rusfertide in Polycythemia VeraSrdan Verstovsek, MD, PhD, discusses the potential for rusfertide in polycythemia vera.
Latest:
PERSIST-1 and PERSIST-2 Trials in MyelofibrosisExpert hematologist/oncologists review the use of pacritinib for the treatment of myelofibrosis, as seen in the PERSIST-1 and PERSIST-2 trials.
Latest:
Bone Marrow Transplant for Patients With MFExpert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.
Latest:
Dr. Chittoor on Targetable Mutations and Respective Treatments in NSCLCSreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.
Latest:
Dr. Ramaswamy Discusses Tumor HeterogeneityDr. Sridhar Ramaswamy from the Massachusetts General Hospital Cancer Center Discusses Tumor Heterogeneity
Latest:
Dr. Sridhar on Nab-Paclitaxel in Urothelial CancerSrikala Sridhar, MD, MSc, from the University of Toronto, Canada, discusses the results of a single arm phase II trial examining nab-paclitaxel as a secondary treatment for urothelial cancer.
Latest:
Colorectal Cancer: Right Test, Right TimeColorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease, with molecular features defining emerging subtypes. Understanding which tests to order in which cases can better direct care for our patients. Increasingly, panel testing has advantages over individual genetic testing.
Latest:
Dr. Levine on Palliative Care for NSCLCStacie Levine, MD, associate professor of Medicine, director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, University of Chicago Medicine, discusses the benefits of palliative care for patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Loeb on the Impact of Additional Testing for Prostate CancerStacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses the impact of different genomic tests for patients with prostate cancer.
Latest:
Giants of Cancer Care® Announces the 11th Annual Class of InducteesOncLive®, the nation’s leading multimedia resource for oncology professionals and Pfizer (platinum sponsor) and Exelixis and Stemline (gold sponsors), are pleased to announce the inductees of the 11th Annual Giants of Cancer Care recognition program.
Latest:
Dr. Liauw on RT Advancements in Prostate CancerStanley Liauw, MD, associate professor at the University of Chicago Medicine, discusses the advancements in radiation therapy (RT) over the last several years, and how he has seen the treatment affect his patients.
Latest:
Dr. Stanley Yap on Sequential Therapy for Muscle-Invasive Bladder CancerStanley Yap, MD, assistant professor, urologic oncology, UC Davis Comprehensive Cancer Center, discusses sequential therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Latest:
Medicaid Expansion Plans Provide Novel Approaches for Healthcare CoverageThe US Supreme Court's decision to uphold the Affordable Care Act but allow states to decide whether to expand Medicaid has raised a question in many states: Where political leaders have been opposed or split on President Obama's healthcare reforms, is it smart or foolish to cover more people?
Latest:
Dr. Aebi on Adjuvant Chemo in Recurrent Breast CancerStefan Aebi, MD, from the Luzerner Kantonsspital, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women recurrent breast cancer.
Latest:
Dr. Faderl on Chemotherapy and FLT3 Inhibitors in AMLStefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, discusses combining and sequencing chemotherapy and FLT3 inhibitors for the treatment of patients with acute myeloid leukemia (AML).
Latest:
Stefani Spranger on the Role of CD8 T Cells in MelanomaStefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago Medicine, discusses how the presence or absence of CD8 T cells can affect treatment approaches for patients with melanoma.
Latest:
Developing Treatment for Invasive Lobular CarcinomaSteffi Oesterreich, PhD, professor and vice chair of Precision and Translational Pharmacology, University of Pittsburgh, discusses developing treatment for patients with invasive lobular carcinoma (ILC).
Latest:
Dr. Grupp on the Optimal Setting of CAR T-Cell Therapy in ALLStephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the placement of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with acute lymphoblastic leukemia (ALL).
